U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Links shared publicly online about this topic.
- 103total visits
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.
View full resource at drugs.com
Tags: Arthritis, Rheumatoid Arthritis, Rheumatoid Arthritis Medication, Diet and Nutrition, Drug, FDA, Orencia
Most Recently Shared on August 2, 2011 at 12:14 am By:
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-A... http://bit.ly/qnjY9u #drug
U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
drugs.com — “Orencia (abatacept) is used for the treatment of rheumatoid arthritis. Information from Drugs.com includes Orencia side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on August 2, 2011 at 12:27 am By:
FDA Approves Subcutaneous Formulation of Orencia - http://bit.ly/pjN8oc
Advertisement
